In our previous study, we investigated in de novo PD patients salivary biomarkers targeting different molecular pathways, including alpha‐synuclein (a‐syn), tau pathology, autophagy (MAPLC3beta), and inflammation (TNFalpha). The gene discussed is SNCA; the disease is Parkinson disease.